Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Launches New Immunoassay Kits

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Ready-to-use kits are fully qualified for reliable use in clinical research.

Merck Millipore has announced the release of five new immunoassay kits designed specifically for use on the Gyrolab™ workstation.

The new, fully qualified GyroMark™ HT kits from Merck Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits.

Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, approximately 500 samples can be analyzed within four hours.

"Our collaboration with Gyros will fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform," says Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at Merck Millipore.

The initial launch includes five assays for important metabolic and toxicity biomarkers, such as GLP-1, Insulin, Clusterin and KIM-1. Merck Millipore plans to release additional kits this year, and is offering custom kits for companies with specific needs or unique or novel antibodies.

Because the Gyrolab™ platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings.

GyroMark™ HT assays provide accuracy over a four-log dynamic range (compared to two logs for ELISAs), elimination of cross-talk and plate position artifacts, and simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference.

Gyros' Global Marketing Director Maria Hjortsmark commented: "The Gyrolab™ platform revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that Merck Millipore has chosen to work with us to develop off-the-shelf kits, to further reduce time to results that will free up analyst time, and offering an easier route to robust, reproducible data."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Partners with Gyros
Partnership to develop, manufacture and commercialize kits on the Gyrolab™ immunoassay platform.
Tuesday, July 16, 2013
Merck Millipore Announces Partnership with NIH Consortium
Adds more than 140 peer-validated neuroscience-specific monoclonal antibodies to portfolio.
Tuesday, October 16, 2012
Scientific News
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Breaking the Brain’s Garbage Disposal
The children’s ataxia gene problem turned out to be not such a big deal genetically — it was such a slight mutation that it barely changed the way the cells made the protein.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!